Enzon Pharmaceuticals Inc
Enzon Pharmaceuticals, Inc. does not have significant operations. Previously, it was engaged in the sale of its patented drug product, PegIntron. The company was formerly known as Enzon, Inc and changed its name to Enzon Pharmaceuticals, Inc. in December 2002. Enzon Pharmaceuticals, Inc. was incorporated in 1981 and is headquartered in Cranford, New Jersey.
Enzon Pharmaceuticals Inc (ENZN) - Net Assets
Latest net assets as of September 2025: $-923.00K USD
Based on the latest financial reports, Enzon Pharmaceuticals Inc (ENZN) has net assets worth $-923.00K USD as of September 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($43.69 Million) and total liabilities ($44.62 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $-923.00K |
| % of Total Assets | -2.11% |
| Annual Growth Rate | -13.74% |
| 5-Year Change | -93.71% |
| 10-Year Change | -83.37% |
| Growth Volatility | 260.41 |
Enzon Pharmaceuticals Inc - Net Assets Trend (1999–2024)
This chart illustrates how Enzon Pharmaceuticals Inc's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Enzon Pharmaceuticals Inc (1999–2024)
The table below shows the annual net assets of Enzon Pharmaceuticals Inc from 1999 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | $3.01 Million | -14.18% |
| 2023-12-31 | $3.50 Million | -92.36% |
| 2022-12-31 | $45.89 Million | +842.69% |
| 2021-12-31 | $4.87 Million | -89.82% |
| 2020-12-31 | $47.82 Million | +689.76% |
| 2019-12-31 | $6.05 Million | -59.61% |
| 2018-12-31 | $14.99 Million | +63.97% |
| 2017-12-31 | $9.14 Million | -11.49% |
| 2016-12-31 | $10.33 Million | -42.89% |
| 2015-12-31 | $18.09 Million | -38.89% |
| 2014-12-31 | $29.60 Million | +463.33% |
| 2013-12-31 | $5.25 Million | -93.22% |
| 2012-12-31 | $77.47 Million | -60.71% |
| 2011-12-31 | $197.18 Million | -40.58% |
| 2010-12-31 | $331.86 Million | +522.82% |
| 2009-12-31 | $53.28 Million | +27.90% |
| 2008-12-31 | $41.66 Million | +13.91% |
| 2007-12-31 | $36.57 Million | +164.80% |
| 2006-12-31 | $-56.44 Million | -127.73% |
| 2004-12-31 | $203.50 Million | -29.61% |
| 2003-12-31 | $289.09 Million | -0.85% |
| 2002-12-31 | $291.58 Million | +53.07% |
| 2001-12-31 | $190.50 Million | +37.06% |
| 2000-12-31 | $138.99 Million | +14.90% |
| 1999-12-31 | $120.96 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Enzon Pharmaceuticals Inc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 6989200000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Other Components | $72.90 Million | 2423.54% |
| Total Equity | $3.01 Million | 100.00% |
Enzon Pharmaceuticals Inc Competitors by Market Cap
The table below lists competitors of Enzon Pharmaceuticals Inc ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Tempest Minerals Ltd
AU:TEM
|
$3.01 Million |
|
FirstCaution SA
PA:MLFIR
|
$3.01 Million |
|
Qualigen Therapeutics Inc
NASDAQ:QLGN
|
$3.01 Million |
|
Mehadrin
TA:MEDN
|
$3.01 Million |
|
COFLE S.P.A.
F:Y9A
|
$3.01 Million |
|
Polyram Plastic Industries Ltd
TA:POLP
|
$3.01 Million |
|
One World Lithium Inc
OTCQB:OWRDF
|
$3.01 Million |
|
AGATOS S.P.A.
F:5JS1
|
$3.01 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Enzon Pharmaceuticals Inc's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 3,505,000 to 3,008,000, a change of -497,000 (-14.2%).
- Net income of 778,000 contributed positively to equity growth.
- Dividend payments of 1,275,000 reduced retained earnings.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $778.00K | +25.86% |
| Dividends Paid | $1.27 Million | -42.39% |
| Total Change | $- | -14.18% |
Book Value vs Market Value Analysis
This analysis compares Enzon Pharmaceuticals Inc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 2.47x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
- The price-to-book ratio has increased from 0.84x to 2.47x over the analyzed period, suggesting growing market confidence.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2013-12-31 | $0.12 | $0.10 | x |
| 2014-12-31 | $0.67 | $0.10 | x |
| 2015-12-31 | $0.41 | $0.10 | x |
| 2016-12-31 | $0.23 | $0.10 | x |
| 2017-12-31 | $0.21 | $0.10 | x |
| 2018-12-31 | $0.34 | $0.10 | x |
| 2019-12-31 | $0.14 | $0.10 | x |
| 2020-12-31 | $0.64 | $0.10 | x |
| 2021-12-31 | $0.07 | $0.10 | x |
| 2022-12-31 | $0.62 | $0.10 | x |
| 2023-12-31 | $0.05 | $0.10 | x |
| 2024-12-31 | $0.04 | $0.10 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Enzon Pharmaceuticals Inc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 25.86%
- The company demonstrates strong efficiency in generating profits from shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 2992.31%
- • Asset Turnover: 0.00x
- • Equity Multiplier: 15.68x
- Recent ROE (25.86%) is below the historical average (47.77%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2000 | 8.29% | 36.49% | 0.06x | 3.95x | $-2.37 Million |
| 2001 | 24.05% | 60.43% | 0.12x | 3.21x | $26.76 Million |
| 2002 | 15.68% | 31.23% | 0.20x | 2.50x | $16.57 Million |
| 2003 | 1.46% | 2.48% | 0.23x | 2.50x | $-24.70 Million |
| 2007 | 227.09% | 44.75% | 0.44x | 11.49x | $79.40 Million |
| 2009 | 1.28% | 0.37% | 0.55x | 6.24x | $-4.65 Million |
| 2010 | 53.41% | 311.14% | 0.12x | 1.47x | $144.06 Million |
| 2011 | -10.53% | -43.19% | 0.14x | 1.74x | $-40.48 Million |
| 2012 | -3.59% | -6.53% | 0.21x | 2.58x | $-10.53 Million |
| 2013 | 345.39% | 52.62% | 4.84x | 1.36x | $17.62 Million |
| 2014 | 97.27% | 92.37% | 0.89x | 1.18x | $25.83 Million |
| 2015 | 119.61% | 123.95% | 0.76x | 1.27x | $19.83 Million |
| 2016 | -10.90% | -13.44% | 0.74x | 1.09x | $-2.16 Million |
| 2017 | 59.55% | 64.98% | 0.88x | 1.04x | $4.53 Million |
| 2018 | 39.01% | 84.55% | 0.45x | 1.03x | $4.35 Million |
| 2019 | -16.17% | -472.95% | 0.03x | 1.07x | $-1.58 Million |
| 2020 | -2.74% | -2521.15% | 0.00x | 1.01x | $-6.09 Million |
| 2021 | -9.63% | -66.90% | 0.01x | 9.81x | $-955.80K |
| 2022 | -0.41% | -715.38% | 0.00x | 1.04x | $-4.78 Million |
| 2023 | 39.17% | 0.00% | 0.00x | 13.61x | $1.02 Million |
| 2024 | 25.86% | 2992.31% | 0.00x | 15.68x | $477.20K |
Industry Comparison
This section compares Enzon Pharmaceuticals Inc's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $59,082,939
- Average return on equity (ROE) among peers: -341.19%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Enzon Pharmaceuticals Inc (ENZN) | $-923.00K | 8.29% | N/A | $3.01 Million |
| Aadi Bioscience Inc (AADI) | $-124.24K | 0.00% | 0.00x | $17.03 Million |
| America Great Health (AAGH) | $-992.37K | 0.00% | 0.00x | $2.12 Million |
| Ascentage Pharma Group International (AAPG) | $70.63 Million | -1310.51% | 34.40x | $2.25 Billion |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-27.92 Million | 0.00% | 0.00x | $59.18 Million |
| ABIVAX Société Anonyme (AAVXF) | $196.01 Million | -75.37% | 0.67x | $377.86 Million |
| Abcellera Biologics Inc (ABCL) | $10.25 Million | -21.57% | 1.29x | $738.02 Million |
| Abeona Therapeutics Inc (ABEO) | $489.00K | -1919.02% | 38.85x | $202.79 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $188.78 Million | -22.70% | 0.04x | $108.65 Million |
| Abpro Holdings, Inc. (ABP) | $-22.46 Million | 0.00% | 0.00x | $2.00 Million |
| Absci Corp (ABSI) | $176.18 Million | -62.76% | 0.23x | $345.85 Million |